The metabolic syndrome and Alzheimer disease.

BACKGROUND The metabolic syndrome is a risk factor for cardiovascular diseases, which have been linked to Alzheimer disease. However, a link between Alzheimer disease and the metabolic syndrome has not yet been established. OBJECTIVE To investigate the relationship between the metabolic syndrome and Alzheimer disease. DESIGN, SETTING, AND PARTICIPANTS Case-control study of 50 consecutive patients diagnosed with probable Alzheimer disease from the Memory Disorders Clinics, Launceston, Australia, and Bristol, England, and 75 cognitively normal controls. MAIN OUTCOME MEASURES The odds ratio of the metabolic syndrome as defined by the National Cholesterol Education Program Adult Treatment Panel III. RESULTS Compared with controls, patients with Alzheimer disease had a significantly larger mean waist circumference, higher mean plasma concentrations of triglycerides and glucose, and a lower mean plasma concentration of high-density lipoprotein cholesterol, but they had lower mean systolic blood pressure. The metabolic syndrome was associated with Alzheimer disease (odds ratio, 3.2; 95% confidence interval, 1.2-8.4; P = .02), and this association was strengthened when the hypertension component was excluded (odds ratio, 7.0; 95% confidence interval, 2.7-18.3; P < .001). All of the analyses were adjusted for age, sex, and location. CONCLUSIONS This study suggests that Alzheimer disease is associated with the metabolic syndrome. This could have implications for the prevention and treatment of Alzheimer disease.

[1]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[2]  S. Teutsch,et al.  THIRD NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES III); NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP). NCEP-DEFI NED METABOLIC SYNDROME, DIABETES, AND PREVALENCE OF CORONARY HEART DISEASE AMONG NHANES III PARTICIPANTS AGE 50 YEARS AND OLDER , 2003 .

[3]  M. Sorrentino Implications of the metabolic syndrome: the new epidemic. , 2005, The American journal of cardiology.

[4]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[5]  G. Reaven Insulin resistance, cardiovascular disease, and the metabolic syndrome: how well do the emperor's clothes fit? , 2004, Diabetes care.

[6]  Vascular factors and Alzheimer disease. , 1999, Alzheimer disease and associated disorders.

[7]  D. Bennett,et al.  Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. , 2004, Archives of neurology.

[8]  S. Teutsch,et al.  NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. , 2003, Diabetes.

[9]  K. Maurer,et al.  Third national health and nutrition examination survey , 1985 .

[10]  A. Newman,et al.  The metabolic syndrome, inflammation, and risk of cognitive decline. , 2004, JAMA.

[11]  P. Greengard,et al.  Stimulation of β-Amyloid Precursor Protein Trafficking by Insulin Reduces Intraneuronal β-Amyloid and Requires Mitogen-Activated Protein Kinase Signaling , 2001, The Journal of Neuroscience.

[12]  B. Winblad,et al.  The age-dependent relation of blood pressure to cognitive function and dementia , 2005, The Lancet Neurology.

[13]  M. Michikawa Cholesterol paradox: Is high total or low HDL cholesterol level a risk for Alzheimer's disease? , 2003, Journal of neuroscience research.

[14]  C M Burchfiel,et al.  Metabolic Cardiovascular Syndrome and Risk of Dementia in Japanese-American Elderly Men: The Honolulu-Asia Aging Study , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[15]  S. Craft,et al.  The Role of Insulin Resistance in the Pathogenesis of Alzheimer’s Disease , 2003, CNS drugs.

[16]  A. Hofman,et al.  Cerebral hypoperfusion and clinical onset of dementia: The Rotterdam study , 2005, Annals of neurology.